Mineralys Therapeutics (NASDAQ:MLYS) Issues Earnings Results, Misses Estimates By $0.30 EPS

Mineralys Therapeutics (NASDAQ:MLYS) issued its quarterly earnings results on Monday. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.30), Zacks reports. During the same quarter in the prior year, the company posted ($0.57) earnings per share.

Mineralys Therapeutics Trading Down 10.3 %

MLYS traded down $1.54 on Tuesday, reaching $13.38. The stock had a trading volume of 397,621 shares, compared to its average volume of 179,600. The company has a market capitalization of $665.39 million, a price-to-earnings ratio of -5.51 and a beta of 1.71. Mineralys Therapeutics has a fifty-two week low of $5.85 and a fifty-two week high of $16.91. The firm has a 50-day moving average of $12.95 and a 200-day moving average of $12.64.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Mineralys Therapeutics in a research report on Tuesday.

Insider Activity

In related news, CFO Adam Scott Levy sold 10,757 shares of the firm’s stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $13.57, for a total value of $145,972.49. Following the completion of the transaction, the chief financial officer now owns 236,854 shares in the company, valued at $3,214,108.78. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider David Malcom Rodman sold 25,482 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $15.03, for a total transaction of $382,994.46. Following the completion of the transaction, the insider now directly owns 135,974 shares in the company, valued at $2,043,689.22. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Adam Scott Levy sold 10,757 shares of the company’s stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $13.57, for a total value of $145,972.49. Following the completion of the sale, the chief financial officer now owns 236,854 shares in the company, valued at $3,214,108.78. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 51,510 shares of company stock valued at $735,431. 33.24% of the stock is currently owned by corporate insiders.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.